Socio-demographics | | |
Sex, n (%), males | 131 (77.51) | 167 (56) |
Age, years: mean (SD) | 29.86 (9.27) | 30.42 (10.96) |
Education, years: mean (SD) | 20.21 (25.7) | 21.75 (25) |
Cognitive and clinical variables | | |
Full-scale IQ total: mean (SD) | 97.86 (16.5) | 110.34 (15.74) |
Age of onset, years: mean (SD)b | 22.13 (5.28) | |
Duration of illness, years: mean, (SD)c | 6.32 (6.63) | |
PANSS score, total: mean (SD) | 63.34 (19.26) | |
Total positive symptoms | 14.96 (5.82) | |
Total negative symptoms | 16.27 (6.22) | |
Total general symptoms | 31.22 (11.2) | |
Antipsychoticsd | | |
Without medication, n (%) | 7 (4.14) | |
Exclusively typical, n (%) | 23 (13.6) | |
Exclusively atypical, n (%) | 89 (52.66) | |
Both, n (%) | 4 (2.36) | |
Cumulative dose exposure per scan (mg): mean (SD) | 27,5837.8 (39,7345.9) | |
Missing, n (%) | 103 (61.54) | |
| FEP patients (n = 89) | HIs (n = 61) |
Socio-demographics | | |
Sex, n (%), males | 56 (70) | 36 (62) |
Age, years: mean (SD) | 21.55 (4.66) | 22.85 (5.14) |
Cognitive and clinical variables | | |
Estimated IQ total: mean (SD) | 92.40 (15.23) | 106.58 (11.58) |
Age of onset, years: mean (SD)b | 20.83 (4.64) | |
Duration of illness, years: mean, (SD)c | 157.88 (109.6) | |
PANSS score, total: mean (SD) | 74.7 (21.68) | |
Total positive symptoms | 18.20 (7.6) | |
Total negative symptoms | 18.61 (8.15) | |
Total general symptoms | 37.89 (11.41) | |
Antipsychotic use (AP)d | | |
Use of AP at scan, n (%) | 74 (93%) | |
Cumulative dose at scan (mg): mean (SD) | 33,330.95 (40,504.16) | |